Preliminary data shows that arbutus' capsid inhibitor, ab-836 is generally safe and well-tolerated and provides robust antiviral activity

Warminster, pa., dec. 01, 2021 (globe newswire) -- arbutus biopharma corporation (nasdaq: abus), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of assets with different modes of action to provide a cure for people with chronic hepatitis b virus (chbv) infection and to treat coronaviruses (including covid-19), today announced preliminary data from its on-going phase 1a/1b clinical trial demonstrating that its next generation capsid inhibitor, ab-836, is generally safe and well-tolerated in both healthy subjects and patients with chbv and provides robust antiviral activity.
ABUS Ratings Summary
ABUS Quant Ranking